Sanofi and REVOLUTION enter into new oncology collaboration

19 July 2018

France’s Sanofi (Euronext: SAN) is launching a partnership with Californian cancer specialist REVOLUTION Medicines to develop targeted therapies based on the biology of the cellular enzyme SHP2.

The collaboration is focused primarily on developing therapies for non-small cell lung cancer, based on precision oncology discoveries by REVOLUTION and the firm’s preclinical work on RMC-4630, a small molecule inhibitor of SHP2.

The firms will jointly contribute to an R&D program to develop SHP2 inhibitors, which are designed to reduce cell growth signaling that is overactive in cancer, with first-in-human clinical trials with RMC-4630 expected in the second half of this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK